Clinical Trial Update: Immunologic Response to Secukinumab in Plaque Psoriasis [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating immunologic response to secukinumab in patients with psoriasis shows completed results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Psoriasis | Phase 4 | Status: COMPLETED | Results posted: 2020-08-27